Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT01155362
PHASE2

PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

Sponsor: Celularity Incorporated

View on ClinicalTrials.gov

Summary

This Phase 2a study evaluated the efficacy, safety, and tolerability of intravenous human placenta-derived cells (PDA001) compared with placebo in adults with moderate-to-severe Crohn's disease. Three PDA001 dose levels were evaluated.

Official title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2010-08

Completion Date

2014-04

Last Updated

2026-07-07

Healthy Volunteers

No

Conditions

Interventions

BIOLOGICAL

Human Placenta-Derived Cells PDA001 Intravenous Infusion

DRUG

Vehicle Control

Locations (13)

Cedars Sinai Medical Center

Los Angeles, California, United States

University of California, Irvine

Orange, California, United States

Yale School of Medicine Digestive Diseases

New Haven, Connecticut, United States

University of Florida

Gainesville, Florida, United States

University of Chicago Medical Center

Chicago, Illinois, United States

Indiana University

Indianapolis, Indiana, United States

Mt Sinai Hospital

New York, New York, United States

Rochester General Hospital

Rochester, New York, United States

Stony Brook University

Stony Brook, New York, United States

Case Western Reserve University

Cleveland, Ohio, United States

Vanderbilt University

Nashville, Tennessee, United States

Baylor College of Medicine

Houston, Texas, United States

McGuire VA Medical Center

Richmond, Virginia, United States